Severe Asthma Management
Severe asthma patients account for as much as 60% of all asthma healthcare costs, and proper management of severe disease is essential.
Tag: Trelegy Ellipta
Severe Asthma Management
Severe asthma patients account for as much as 60% of all asthma healthcare costs, and proper management of severe disease is essential.
Read More
FDA Approves Trelegy Ellipta for Asthma
The US FDA has approved a new indication for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) for the treatment of asthma in patients aged 18 years and older.
Read MoreTriple Therapy More Effective for COPD than Dual Inhalers?
Trelegy Ellipta, a triple therapy delivered in a single inhaler, reduces moderate to severe exacerbations in COPD to a greater extent than dual-inhaler therapy in patients at high risk for exacerbations, according to the IMPACT...
Read MoreCOPD Triple-combo Therapy Gets Expanded Indication
Trelegy Ellipta, a triple-combination LABA/ICS inhaled treatment for COPD, has been approved for an expanded indication by the FDA, according to GlaxoSmithKline and Innoviva Inc.
Read More
Phase 3 Study Begins on Trelegy Ellipta for Asthma
GlaxoSmithKline and Innoviva Inc have initiated a phase III study investigating the effects of once-daily closed triple combination therapy fluticasone furoate/umeclidinium/vilanterol for asthma.
Read More